JP2024525580A5 - - Google Patents
Info
- Publication number
- JP2024525580A5 JP2024525580A5 JP2024500312A JP2024500312A JP2024525580A5 JP 2024525580 A5 JP2024525580 A5 JP 2024525580A5 JP 2024500312 A JP2024500312 A JP 2024500312A JP 2024500312 A JP2024500312 A JP 2024500312A JP 2024525580 A5 JP2024525580 A5 JP 2024525580A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- membered
- pharmaceutically acceptable
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219167P | 2021-07-07 | 2021-07-07 | |
| US63/219,167 | 2021-07-07 | ||
| US202263354020P | 2022-06-21 | 2022-06-21 | |
| US63/354,020 | 2022-06-21 | ||
| PCT/US2022/036409 WO2023283372A1 (en) | 2021-07-07 | 2022-07-07 | Compounds for targeting degradation of irak4 proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525580A JP2024525580A (ja) | 2024-07-12 |
| JP2024525580A5 true JP2024525580A5 (cg-RX-API-DMAC10.html) | 2025-07-11 |
Family
ID=82748787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500312A Pending JP2024525580A (ja) | 2021-07-07 | 2022-07-07 | Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250018046A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4366834A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024525580A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023283372A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| WO2024020522A1 (en) * | 2022-07-22 | 2024-01-25 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of irak-4 |
| CN117777126A (zh) * | 2022-09-29 | 2024-03-29 | 武汉人福创新药物研发中心有限公司 | 作为irak4降解剂的咪唑并吡啶类化合物及其用途 |
| EP4638447A1 (en) * | 2022-12-21 | 2025-10-29 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4389747A1 (en) * | 2022-12-21 | 2024-06-26 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4428134A1 (en) * | 2023-03-10 | 2024-09-11 | Dark Blue Therapeutics Ltd | Protac degraders of mllt1 and/or mllt3 |
| CN116251488B (zh) * | 2023-03-13 | 2024-05-24 | 石河子大学 | 一种用于分离二氧化碳的含氨基功能材料及其制备方法和应用 |
| WO2024208256A1 (zh) * | 2023-04-03 | 2024-10-10 | 上海汇伦医药股份有限公司 | 靶向蛋白降解化合物及其制备方法和应用 |
| KR20260005340A (ko) * | 2023-05-30 | 2026-01-09 | 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 | 트리시클릭 화합물, 이의 제조 방법 및 적용 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｋｒａｓの分解のためのヘテロ二官能性化合物 |
| EP4763839A1 (en) * | 2023-08-15 | 2026-06-24 | Pamplona Therapeutics (Shenzhen) Co., Ltd. | Compound targeting irak protein inhibition or degradation and use thereof |
| CN118955497B (zh) * | 2023-08-21 | 2025-10-31 | 泰诺瑞(天津)生物科技有限责任公司 | 一种咪唑并[1,2-a]吡啶类IRAK4降解剂及其应用 |
| CN122270449A (zh) * | 2023-12-13 | 2026-06-23 | 百济神州(苏州)生物科技有限公司 | 通过将irak4抑制剂与e3连接酶配体缀合来降解irak4以及使用方法 |
| WO2025130871A1 (zh) * | 2023-12-20 | 2025-06-26 | 爱科诺生物医药(香港)有限公司 | 具有irak4和flt3蛋白双重降解活性的化合物，包含其的药物组合物，及其应用 |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| MX375925B (es) * | 2014-06-25 | 2025-03-07 | Hoffmann La Roche | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP3634960A1 (en) | 2017-06-09 | 2020-04-15 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019023553A1 (en) | 2017-07-28 | 2019-01-31 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11065231B2 (en) * | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CN110835338A (zh) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| JP7576552B2 (ja) | 2019-01-18 | 2024-10-31 | バイオジェン・エムエイ・インコーポレイテッド | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020259626A1 (zh) * | 2019-06-26 | 2020-12-30 | 南京明德新药研发有限公司 | 作为irak4抑制剂的咪唑并吡啶类化合物 |
| PH12022500002A1 (en) * | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) * | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN114728936A (zh) * | 2019-10-29 | 2022-07-08 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的双功能化合物 |
-
2022
- 2022-07-07 WO PCT/US2022/036409 patent/WO2023283372A1/en not_active Ceased
- 2022-07-07 EP EP22748646.1A patent/EP4366834A1/en active Pending
- 2022-07-07 US US18/576,933 patent/US20250018046A1/en active Pending
- 2022-07-07 JP JP2024500312A patent/JP2024525580A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527570A5 (cg-RX-API-DMAC10.html) | ||
| CN108463458B (zh) | ROR-γ的调节剂 | |
| CN112218863B (zh) | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 | |
| JP5914642B2 (ja) | ピラゾール誘導体 | |
| US20080280948A1 (en) | Modulators of amyloid beta | |
| AU2015315687B2 (en) | P2X7 modulators | |
| AU2017279027A1 (en) | Chemical Compounds | |
| BR112020000086A2 (pt) | derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças | |
| JP2022507013A5 (cg-RX-API-DMAC10.html) | ||
| WO2018097945A1 (en) | Heteroaryl-substituted triazoles as apj receptor agonists | |
| TW472054B (en) | Azetidines | |
| TW201406749A (zh) | 磺醯胺衍生物及彼等用於改良藥物之藥物動力學之用途 | |
| RS56747B1 (sr) | Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest | |
| WO2023225664A1 (en) | Lactam substituted imidazopyridazine il-17a modulators and uses thereof | |
| IL322435A (en) | Covalent modifiers of Akt1 and their uses | |
| CA3243547A1 (en) | INDAZOLE GLUCOCORTICOID RECEPTOR BICYCLIC ANTAGONISTS | |
| AU2018360575A1 (en) | Alkene spirocyclic compounds as farnesoid X receptor modulators | |
| CN109311878B (zh) | 作为γ-分泌酶调节剂的三唑并吡啶类化合物 | |
| WO2004094407A1 (ja) | ５員複素環誘導体 | |
| WO2022217118A1 (en) | Pyrimidine based ras modulators and uses thereof | |
| JP2012513400A (ja) | γ−セクレターゼ調節剤 | |
| WO2003002540A1 (fr) | Compose diamine cyclique presentant un groupe cyclique a cinq elements | |
| JP2025503006A5 (cg-RX-API-DMAC10.html) | ||
| ES2307182T3 (es) | Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas receptores de mglur5. | |
| JP7773016B2 (ja) | 三環式誘導体及びその調製方法と使用 |